Stock Ratings / Industrials / DBD / earnings

PBI (66) NATL (56) VYX (31) PAR (31) ⌘ Pro Terminal →

Diebold Nixdorf Incorporated (DBD) Next Earnings Date & Expected ±8.5% Move

Q: Is DBD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Diebold Nixdorf Incorporated (NYSE: DBD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $59.14 (+1.84% 1D, market cap $1.99B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 16/20. Across 485 tracked Industrials issuers, DBD ranks #153 in composite RQD confidence.

Q: How does DBD compare to PBI and NATL in the Industrials sector?

Within the Industrials sector (Office Equipment/Supplies/Services), DBD carries a Roarable C- (61/100 RQD), trailing P/E of 21.0x, gross margin of 25.3%, and ROIC of 11.5%. By comparison, PBI (Pitney Bowes Inc.) holds a C+ grade (66/100 RQD, P/E 15.6x, ROIC —, cap $2.26B) and NATL (NCR Atleos Corporation) posts a D+ grade (56/100 RQD, P/E 20.9x, ROIC 14.4%, cap $3.38B). Among the 5-stock peer group, PBI leads on earnings multiple (15.6x) while NATL leads on capital efficiency (14.4% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for DBD?

Per DBD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000028823), Diebold Nixdorf Incorporated generated $3.81B in revenue (+1.5% YoY), $94.6M in net income, and $300.7M in free cash flow against $3.85B in total assets and $938.5M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is DBD trading relative to its 50-day, 200-day, and 52-week technical levels?

DBD last traded at $59.14 (+1.84% on volume of 685,821 shares), positioning the stock -9.22% below its 50-day simple moving average ($65.15) and -21.10% below its 200-day simple moving average ($74.96). Across its 52-week range of $52.87 to $92.09, DBD sits at the 16.0% percentile with a 14-day RSI of 27.7 (OVERSOLD (<32)) and an implied next-earnings move of ±8.5% ($54.11 to $64.17).

Q: When is DBD's next earnings date?

Based on SEC filing cadence, Diebold Nixdorf Incorporated (DBD)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is DBD stock expected to move on earnings?

Volatility modeling currently projects a ±8.5% event move for DBD, spanning a range between $54.11 and $64.17.

$59.14 +1.84% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $59.22

Diebold Nixdorf Incorporated (DBD) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $1.99B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $59.22 (+0.14%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 7.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DBD)Realized 20D OHLCV Swing Band: ±8.5%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY DBD SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+16/20 pts (26% of score)

SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (21% of score)

FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 27.7 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$63.67+5% Next Q

Q2 (-2Q)

Grade B-$66.83+3.5% Next Q

Q3 (-1Q)

Grade C+$69.18-14.5% Next Q

Current

Grade C-$59.14+0.5% Hist 90D α

Trajectory: B- (69) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the DBD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, DBD faces multiple-compression risk if 21.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 22.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($65.15) or 200D SMA ($74.96) invalidates the momentum regime and cuts Target Base ($59.94) toward Bear Floor ($46.75).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DBD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DBD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±8.5% Swing Band

±$5.03 Expected Swing

MODEL EARNINGS SETUP GAUGE

DBD Quantitative Pre-Earnings Setup: 61/100

Trailing EPS: $2.82 • YoY Revenue Growth: 1.5%

Model Bullish Setup (61/100)Model Risk Weight (39/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$3.81B	$94.6M	$300.7M	25.3%
FY 2024	2024-12-31	$3.75B	-$16.5M	$149.2M	24.5%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating DBD & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on DBD
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DBD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.00%📐 HORIZONTAL RANGE

2026-10-30O $58.39H $59.14L $52.87C $59.14VOL 739.9K

RES: $105.4SUP: $53.42SMA50: $65.15SMA200: $74.96

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DBD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DBD Butterfly Map → + Track DBD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

14.6%/yr Implied 5Y Growth

vs. +1.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DBD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DBD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DBD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DBD)

Industrials Rank #153 of 485 ⚔️ PBI vs DBD Full Matrix →

1. Head-to-Head Industrials Peer Comparison (DBD vs. PBI, NATL, VYX, PAR)

Industry: Office Equipment/Supplies/Services (13 Tracked Issuers)

Across 485 tracked Industrials securities in the Roarable RQD universe, Diebold Nixdorf Incorporated (DBD) ranks #153 by composite RQD confidence (61/100, grade C-) and #211 by equity capitalization ($1.99B). Within this direct 5-issuer industry benchmark cohort, PBI leads on earnings valuation at 15.6x trailing P/E, while NATL leads on capital efficiency and profitability with 14.4% ROIC and — gross margin. PBI currently holds the highest overall quantitative score in the immediate peer group at 66/100 (C+) compared with DBD at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DBD ACTIVE Diebold Nixdorf Incorporated	C-	61/100	21.0x	25.3%	11.5%	+1.84%	$1.99B	Benchmark Subject
PBI Pitney Bowes Inc.	C+	66/100	15.6x	—	—	-5.62%	$2.26B	/pbi-vs-dbd →
NATL NCR Atleos Corporation	D+	56/100	20.9x	—	14.4%	+0.93%	$3.38B	/natl-vs-dbd →
VYX NCR Voyix Corporation	E	31/100	18.3x	—	1.1%	+3.27%	$1.13B	/vyx-vs-dbd →
PAR PAR Technology Corporation	E	31/100	—	43.5%	-4.9%	+3.55%	$736.3M	/par-vs-dbd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000028823

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Diebold Nixdorf Incorporated (DBD) reported GAAP revenue of $3.81B (+1.5% vs. FY2024 revenue of $3.75B ) , GAAP net income of $94.6M, operating cash flow of $300.7M, and free cash flow of $300.7M (+101.5% YoY). On the balance sheet, DBD closed FY2025 with $3.85B in total assets against $938.5M in total debt (Altman Z-Score: 1.79, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.81B	$94.6M	$300.7M	$300.7M	$3.85B	$938.5M
FY2024 (FY)	2024-12-31	$3.75B	-$16.5M	$149.2M	$149.2M	$3.54B	$927.3M

3. DBD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DBD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Diebold Nixdorf Incorporated (NYSE: DBD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $59.14 (+1.84% 1D, market cap $1.99B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 16/20. Across 485 tracked Industrials issuers, DBD ranks #153 in composite RQD confidence.

How does DBD compare to PBI and NATL in the Industrials sector?

Within the Industrials sector (Office Equipment/Supplies/Services), DBD carries a Roarable C- (61/100 RQD), trailing P/E of 21.0x, gross margin of 25.3%, and ROIC of 11.5%. By comparison, PBI (Pitney Bowes Inc.) holds a C+ grade (66/100 RQD, P/E 15.6x, ROIC —, cap $2.26B) and NATL (NCR Atleos Corporation) posts a D+ grade (56/100 RQD, P/E 20.9x, ROIC 14.4%, cap $3.38B). Among the 5-stock peer group, PBI leads on earnings multiple (15.6x) while NATL leads on capital efficiency (14.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DBD?

Per DBD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000028823), Diebold Nixdorf Incorporated generated $3.81B in revenue (+1.5% YoY), $94.6M in net income, and $300.7M in free cash flow against $3.85B in total assets and $938.5M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DBD trading relative to its 50-day, 200-day, and 52-week technical levels?

DBD last traded at $59.14 (+1.84% on volume of 685,821 shares), positioning the stock -9.22% below its 50-day simple moving average ($65.15) and -21.10% below its 200-day simple moving average ($74.96). Across its 52-week range of $52.87 to $92.09, DBD sits at the 16.0% percentile with a 14-day RSI of 27.7 (OVERSOLD (<32)) and an implied next-earnings move of ±8.5% ($54.11 to $64.17).

DBD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is DBD's next earnings date?

Based on SEC filing cadence, Diebold Nixdorf Incorporated (DBD)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is DBD stock expected to move on earnings?

Volatility modeling currently projects a ±8.5% event move for DBD, spanning a range between $54.11 and $64.17.

Direct Sub-Reports: DBD RQD Cockpit DBD 12M Forecast DBD Earnings & Move DBD Dividends & DRIP DBD Insiders & 13F DBD Whale Options DBD Profit Sankey DBD News & Why